Hypokinesia in Parkinson's disease: influence of age, disease severity, and disease duration.
Identifieur interne : 004967 ( PubMed/Corpus ); précédent : 004966; suivant : 004968Hypokinesia in Parkinson's disease: influence of age, disease severity, and disease duration.
Auteurs : J J Van Hilten ; E A Braat ; E A Van Der Velde ; H A Middelkoop ; J G Van Dijk ; G J Lighart ; R A RoosSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1995.
English descriptors
- KwdEn :
- Activities of Daily Living (classification), Adult, Aged, Aged, 80 and over, Antiparkinson Agents (therapeutic use), Circadian Rhythm (drug effects), Circadian Rhythm (physiology), Drug Therapy, Combination, Female, Humans, Hypokinesia (classification), Hypokinesia (diagnosis), Hypokinesia (drug therapy), Levodopa (therapeutic use), Male, Middle Aged, Motor Activity (drug effects), Motor Activity (physiology), Muscle Rigidity (classification), Muscle Rigidity (diagnosis), Muscle Rigidity (drug therapy), Neurologic Examination (drug effects), Parkinson Disease (classification), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy).
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- classification : Activities of Daily Living, Hypokinesia, Muscle Rigidity, Parkinson Disease.
- diagnosis : Hypokinesia, Muscle Rigidity, Parkinson Disease.
- drug effects : Circadian Rhythm, Motor Activity, Neurologic Examination.
- drug therapy : Hypokinesia, Muscle Rigidity, Parkinson Disease.
- physiology : Circadian Rhythm, Motor Activity.
- Adult, Aged, Aged, 80 and over, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.
Abstract
The aim of this cross-sectional study was to compare the role of aging in measures reflecting diurnal activity and immobility in 60 parkinsonian patients with predominant features of hypokinesia and rigidity and 100 healthy subjects aged 50 to 98 years. In the patients, we also studied the relation between disease duration and subjective and objective measures of disease severity. Motor activity was recorded during 5 successive days at home with a wrist-worn activity monitor. For each subject, two mean measures reflecting the diurnal activity level and the relative proportion of activity and immobility were calculated. Diurnal measures of activity revealed in both groups a prominent absolute reduction of activity and an increase of the time spent without movement ("immobility") with advancing age. Parkinsonian patients showed significantly lower values for both motor-activity measures than did the healthy subjects. The rate of the age-related decline of both diurnal activity measures in both groups, however, is comparable. Disease duration showed no relation with subjective and objective measures reflecting disease severity. This study shows that if care is taken to control for disease severity, the rate of the age-related decline of measures reflecting diurnal activity and immobility is similar in both groups. The lack of relation between disease duration and subjective and objective measures of disease severity suggests that the rate of progression of Parkinson's disease can be reliably studied only by means of longitudinal studies.
DOI: 10.1002/mds.870100404
PubMed: 7565821
Links to Exploration step
pubmed:7565821Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hypokinesia in Parkinson's disease: influence of age, disease severity, and disease duration.</title><author><name sortKey="Van Hilten, J J" sort="Van Hilten, J J" uniqKey="Van Hilten J" first="J J" last="Van Hilten">J J Van Hilten</name><affiliation><nlm:affiliation>Department of Neurology, Academic Hospital, State University of Leiden, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Braat, E A" sort="Braat, E A" uniqKey="Braat E" first="E A" last="Braat">E A Braat</name></author><author><name sortKey="Van Der Velde, E A" sort="Van Der Velde, E A" uniqKey="Van Der Velde E" first="E A" last="Van Der Velde">E A Van Der Velde</name></author><author><name sortKey="Middelkoop, H A" sort="Middelkoop, H A" uniqKey="Middelkoop H" first="H A" last="Middelkoop">H A Middelkoop</name></author><author><name sortKey="Van Dijk, J G" sort="Van Dijk, J G" uniqKey="Van Dijk J" first="J G" last="Van Dijk">J G Van Dijk</name></author><author><name sortKey="Lighart, G J" sort="Lighart, G J" uniqKey="Lighart G" first="G J" last="Lighart">G J Lighart</name></author><author><name sortKey="Roos, R A" sort="Roos, R A" uniqKey="Roos R" first="R A" last="Roos">R A Roos</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1995">1995</date><idno type="RBID">pubmed:7565821</idno><idno type="pmid">7565821</idno><idno type="doi">10.1002/mds.870100404</idno><idno type="wicri:Area/PubMed/Corpus">004967</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hypokinesia in Parkinson's disease: influence of age, disease severity, and disease duration.</title><author><name sortKey="Van Hilten, J J" sort="Van Hilten, J J" uniqKey="Van Hilten J" first="J J" last="Van Hilten">J J Van Hilten</name><affiliation><nlm:affiliation>Department of Neurology, Academic Hospital, State University of Leiden, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Braat, E A" sort="Braat, E A" uniqKey="Braat E" first="E A" last="Braat">E A Braat</name></author><author><name sortKey="Van Der Velde, E A" sort="Van Der Velde, E A" uniqKey="Van Der Velde E" first="E A" last="Van Der Velde">E A Van Der Velde</name></author><author><name sortKey="Middelkoop, H A" sort="Middelkoop, H A" uniqKey="Middelkoop H" first="H A" last="Middelkoop">H A Middelkoop</name></author><author><name sortKey="Van Dijk, J G" sort="Van Dijk, J G" uniqKey="Van Dijk J" first="J G" last="Van Dijk">J G Van Dijk</name></author><author><name sortKey="Lighart, G J" sort="Lighart, G J" uniqKey="Lighart G" first="G J" last="Lighart">G J Lighart</name></author><author><name sortKey="Roos, R A" sort="Roos, R A" uniqKey="Roos R" first="R A" last="Roos">R A Roos</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1995" type="published">1995</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living (classification)</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (therapeutic use)</term><term>Circadian Rhythm (drug effects)</term><term>Circadian Rhythm (physiology)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Hypokinesia (classification)</term><term>Hypokinesia (diagnosis)</term><term>Hypokinesia (drug therapy)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Motor Activity (drug effects)</term><term>Motor Activity (physiology)</term><term>Muscle Rigidity (classification)</term><term>Muscle Rigidity (diagnosis)</term><term>Muscle Rigidity (drug therapy)</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (classification)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Activities of Daily Living</term><term>Hypokinesia</term><term>Muscle Rigidity</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hypokinesia</term><term>Muscle Rigidity</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Circadian Rhythm</term><term>Motor Activity</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypokinesia</term><term>Muscle Rigidity</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Circadian Rhythm</term><term>Motor Activity</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this cross-sectional study was to compare the role of aging in measures reflecting diurnal activity and immobility in 60 parkinsonian patients with predominant features of hypokinesia and rigidity and 100 healthy subjects aged 50 to 98 years. In the patients, we also studied the relation between disease duration and subjective and objective measures of disease severity. Motor activity was recorded during 5 successive days at home with a wrist-worn activity monitor. For each subject, two mean measures reflecting the diurnal activity level and the relative proportion of activity and immobility were calculated. Diurnal measures of activity revealed in both groups a prominent absolute reduction of activity and an increase of the time spent without movement ("immobility") with advancing age. Parkinsonian patients showed significantly lower values for both motor-activity measures than did the healthy subjects. The rate of the age-related decline of both diurnal activity measures in both groups, however, is comparable. Disease duration showed no relation with subjective and objective measures reflecting disease severity. This study shows that if care is taken to control for disease severity, the rate of the age-related decline of measures reflecting diurnal activity and immobility is similar in both groups. The lack of relation between disease duration and subjective and objective measures of disease severity suggests that the rate of progression of Parkinson's disease can be reliably studied only by means of longitudinal studies.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">7565821</PMID><DateCreated><Year>1995</Year><Month>11</Month><Day>03</Day></DateCreated><DateCompleted><Year>1995</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>1995</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Hypokinesia in Parkinson's disease: influence of age, disease severity, and disease duration.</ArticleTitle><Pagination><MedlinePgn>424-32</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this cross-sectional study was to compare the role of aging in measures reflecting diurnal activity and immobility in 60 parkinsonian patients with predominant features of hypokinesia and rigidity and 100 healthy subjects aged 50 to 98 years. In the patients, we also studied the relation between disease duration and subjective and objective measures of disease severity. Motor activity was recorded during 5 successive days at home with a wrist-worn activity monitor. For each subject, two mean measures reflecting the diurnal activity level and the relative proportion of activity and immobility were calculated. Diurnal measures of activity revealed in both groups a prominent absolute reduction of activity and an increase of the time spent without movement ("immobility") with advancing age. Parkinsonian patients showed significantly lower values for both motor-activity measures than did the healthy subjects. The rate of the age-related decline of both diurnal activity measures in both groups, however, is comparable. Disease duration showed no relation with subjective and objective measures reflecting disease severity. This study shows that if care is taken to control for disease severity, the rate of the age-related decline of measures reflecting diurnal activity and immobility is similar in both groups. The lack of relation between disease duration and subjective and objective measures of disease severity suggests that the rate of progression of Parkinson's disease can be reliably studied only by means of longitudinal studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Hilten</LastName><ForeName>J J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Academic Hospital, State University of Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braat</LastName><ForeName>E A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>van der Velde</LastName><ForeName>E A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Middelkoop</LastName><ForeName>H A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>van Dijk</LastName><ForeName>J G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Lighart</LastName><ForeName>G J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Roos</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000203">Activities of Daily Living</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002940">Circadian Rhythm</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018476">Hypokinesia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009127">Muscle Rigidity</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7565821</ArticleId><ArticleId IdType="doi">10.1002/mds.870100404</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004967 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 004967 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:7565821
|texte= Hypokinesia in Parkinson's disease: influence of age, disease severity, and disease duration.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:7565821" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |